eIF6: a promising therapeutic target for gastric carcinoma via PI3K/AKT pathway modulation
eIF6's overexpression in GC suggests its role in tumor progression, highlighting its potential as a therapeutic target. The study provides a foundation for developing targeted therapies against eIF6 and emphasizes the need for further research into its regulatory mechanisms in GC.
Authors
- Zhao‐Ru Dong (ORCID: https://orcid.org/0000-0001-6056-2097)
- Wence Zhou (ORCID: https://orcid.org/0000-0002-0529-7777)
- Shuang Hou (ORCID: https://orcid.org/0000-0001-5487-2427)
- Hao Tang (ORCID: https://orcid.org/0000-0003-2202-0515)
Institutions
- Shanghai Jiao Tong University (CN)
- Lanzhou University Second Hospital (CN)
- Songjiang District Central Hospital (CN)
- First Hospital of Lanzhou University (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1186/s12957-025-03746-w
- Citations
- 1
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China